Skip to content
Sign in
Venture capitalBacked 1 network startup

Sands Capital Ventures

Life-sciences and venture arm of Sands Capital ($54B+ AUM); Pulse strategy ($1.3B) backs therapeutics, diagnostics, devices and tools.

Arlington, United States
Ticket
—Not published
Assets under management
—
Founded
1992
Stages
Series Ato Series B and later
Network startups backed
1
Co-investors
0

How they invest

Private life-sciences companies (therapeutics, diagnostics, medical devices, tools) through the Pulse strategy, plus technology ventures. As a growth-oriented manager it favours companies with clinical data or validated products that can scale.

Stage and ticket

Series A and Series B and later; ticket not recorded (Pulse III raised $555M in 2024).

Geography

Global.

What makes them say yes

  • Clinical-stage assets or regulatory clearance
  • Platform potential beyond one product
  • Syndicate with specialist life-sciences co-investors

Red flags

  • Pre-clinical seed companies
  • Non-healthcare businesses (except the separate venture strategy)

Sectors

  • Biotech & life sciences
  • MedTech & devices
  • AI & software

Stages

  • Series A
  • Series B and later

Geographies

  • Global

How to approach

Approach the Life Sciences team (Stephen Zachary, Managing Partner) at Series A/B with clinical data. PolyJoule, the one recorded network deal, sits outside life sciences, so there is no health-sector warm path.

Partners

  • Stephen ZacharyManaging Partner, Life Sciences

Portfolio

1 network startup · no other company

The only recorded network deal is PolyJoule (energy storage), atypical for the Pulse strategy; no network life-sciences holding yet.

Gaps in the portfolio

  • Network therapeutics at Series A
  • Medical devices with FDA clearance
  • Research tools

Network startups

  • PolyJouleSWC 2026 Finalist

    MIT spin-off making lithium-free, non-flammable conductive-polymer batteries for stationary storage, UL9540A-certified and grid-connected since 2021.

    United States · Climate & energy

    • Venture capital (including Series B mentioned by PitchBook, not verified) · $23.9MSource

Network startups that fit

5 analysed

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

KAIST spin-off with acute-kidney-injury drug BX-001N past phase 1 and in phase 2a: a clinical-stage therapeutic at Series A, the Pulse sweet spot.

50%confidence

Evidence from the records

  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea”
  • “Series A”
Intro path
Co-investors include Solbrain Holdings and WeVentures.
First step
Send BILIX's phase 1 data package to the Pulse team.

HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

HKUST polymer therapeutics with a Health Canada-authorised first-in-human trial, $18.6M raised at Series A.

45%confidence

Evidence from the records

  • “Polymer-based therapeutics”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada”
Intro path
Zero2IPO (Pleryon investor).
First step
Pitch Pleryon's next round with trial readouts.

FDA-cleared low-cost automated peritoneal dialysis cycler, built in a DRAP-approved Pakistani factory, preparing first US patients.

FDA 510(k)-cleared home dialysis cycler with a manufacturing base: a de-risked medical device, though raised only at seed so far.

40%confidence

Evidence from the records

  • “FDA 510(k) clearance K243371”
  • “At-home peritoneal dialysis”
First step
Approach at Byonyks' Series A with US launch metrics.

EPFL spin-off making soft, stretchable cortical electrodes for minimally invasive brain interfaces, with first-in-human epilepsy data and a $7.5M seed.

EPFL neural-interface company with first-in-human data, 29 patents and a $7.5M oversubscribed seed; a candidate for a medtech Series A.

40%confidence

Evidence from the records

  • “first-in-human evaluation (soft ECoG in epilepsy surgery) published, 26 papers and 29 patents”
  • “Neurotechnology / brain-computer interfaces”
Intro path
Co-investors PL Capital, Skybound, Connecticut Innovations.
First step
Track Neurosoft's Series A timing and introduce the Pulse team.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

No co-investment documented yet.

Sources